@article{Patrice Chevallier_Myriam Labopin_Gérard Socié_Reza Tabrizi_Sabine Furst_Bruno Lioure_Thierry Guillaume_Jacques Delaunay_Régis Peffault de La Tour_Stéphane Vigouroux_Jean El-Cheikh_Didier Blaise_Mauricette Michallet_Karin Bilger_Noel Milpied_Philippe Moreau_Mohamad Mohty_2014, place={Pavia, Italy}, title={Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial}, volume={99}, url={https://haematologica.org/article/view/7142}, DOI={10.3324/haematol.2014.108563}, abstractNote={We prospectively evaluated the safety and efficacy of a clofarabine, intravenous busulfan and antithymocyte globulin-based reduced-toxicity conditioning (CloB2A2) regimen before allogeneic stem cell transplantation. Thirty high-risk patients (median age: 59 years; acute myeloid leukemia n=11, acute lymphoblastic leukemia n=13; myelodysplastic syndrome n=5, bi-phenotypic leukemia n=1) were included in this phase 2 study. At time of their transplant, 20 and seven patients were in first and second complete remission, respectively, while three patients with myelodysplastic syndrome were responding to chemotherapy or who had not been previously treated. The CloB2A2 regimen consisted of clofarabine 30 mg/m<sup>2</sup>/day for 4 days, busulfan 3.2 mg/kg/day for 2 days and antithymocyte globulin 2.5 mg/kg/day for 2 days. The median follow-up was 23 months. Engraftment occurred in all patients. The 1-year overall survival, leukemia-free survival, relapse incidence and non-relapse mortality rates were 63±9%, 57±9%, 40±9%, and 3.3±3%, respectively. Comparing patients with acute myeloid leukemia/myelodysplastic syndrome <em>versus</em> those with acute lymphoblastic leukemia/bi-phenotypic leukemia, the 1-year overall and leukemia-free survival rates were 75±10% <em>versus</em> 50±13%, respectively (<em>P</em>=0.07) and 69±12% <em>versus</em> 43±13%, respectively (<em>P</em>=0.08), while the 1-year relapse incidence was 25±11% <em>versus</em> 57±14%, respectively (<em>P</em>=0.05). The CloB2A2 regimen prior to allogeneic stem cell transplantation is feasible, allowing for full engraftment and low toxicity. Disease control appears to be satisfactory, especially in patients with acute myeloid leukemia/myelodysplastic syndrome. The trial was registered at <em><a href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</a> no. <a class="external-ref external-ref-type-clintrialgov" href="/lookup/external-ref?link_type=CLINTRIALGOV&amp;access_num=NCT00863148&amp;atom=%2Fhaematol%2F99%2F9%2F1486.atom">NCT00863148</a></em&gt;.}, number={9}, journal={Haematologica}, author={Patrice Chevallier and Myriam Labopin and Gérard Socié and Reza Tabrizi and Sabine Furst and Bruno Lioure and Thierry Guillaume and Jacques Delaunay and Régis Peffault de La Tour and Stéphane Vigouroux and Jean El-Cheikh and Didier Blaise and Mauricette Michallet and Karin Bilger and Noel Milpied and Philippe Moreau and Mohamad Mohty}, year={2014}, month={Aug.}, pages={1486-1491} }